Author

Miles Parkes 1

1 Gastroenterology,Addenbrooke's Hospital,Cambridge,United Kingdom

A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE

James Lindsay, Alan J Lobo, John Snowden, Hannah Berntsson, Mike Bradburn, Lauren Desoysa, Shahida Din, John Gribben, Danny Hind, Ellen Lee, Yash Mahida, Gordon Moran, Peter Irving, Christopher John Hawkey, Miles Parkes, Lizzie Swaby, Simon Travis, Sree Subramanian, Jack Satsangi

ACETARSOL SUPPOSITORIES ARE AN EFFECTIVE AND WELL TOLERATED TREATMENT FOR REFRACTORY PROCTITIS: A COHORT STUDY

Christopher John Kiely, Angela Clark, Joya Bhattacharyya, James C. Lee, Miles Parkes

COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE

James Alexander, Zhigang Liu, Diana Munoz Sandoval, Catherine Reynolds, Hajir Ibraheim, Sulak Anandabaskaran, Aamir Saifuddin, Rocia Castro Seoane, Nikhil Anand, Rachel Nice, Claire Bewshea, Andrea D'Mello, Laura Constable, Gareth R Jones, Sharmili Balarajah, Francesca Fiorentino, Shaji Sebastian, Peter Irving, Lucy Hicks

GENOME-WIDE ANALYSIS OF 53,400 PEOPLE WITH IRRITABLE BOWEL SYNDROME HIGHLIGHTS SHARED PATHWAYS WITH NEUROAFFECTIVE TRAITS

Chris Eijsbouts, Tenghao Zheng, Nicholas A Kennedy, Ferdinando Bonfiglio, Carl Anderson, Joanne Holliday, Jing Shi, Suyash Shringarpure, Alexandru-Ioan Voda, Gianrico Farrugia, Andre Franke, Matthias Hübenthal, Goncalo Abecasis, Matthew Zawistowski, Anne Heidi Skogholt, Kristian Hveem, Tonu Esko, Maris Teder-Laving, Alexa

PROFILE TRIAL: PREDICTING OUTCOMES FOR CROHN’S DISEASE USING A MOLECULAR BIOMARKER

James C. Lee, Daniele Biasci, Nurulamin M Noor, Eoin F. McKinney, Tariq Ahmad, Nina R Lewis, Ailsa L Hart, Paul A Lyons, Miles Parkes, Kenneth GC Smith

THE UK INFLAMMATORY BOWEL DISEASE BIORESOURCE: PROGRESSING FROM GENETICS TO FUNCTION AND CLINICAL TRANSLATION IN CROHN'S DISEASE & ULCERATIVE COLITIS IN ADULTS, YOUNG PEOPLE AND CHILDREN

Laetitia Pele, Rachel Simpkins, Catherine Thorbinson, Rasha Shawky, Sarah Hearn, Holm Uhlig, Miles Parkes

THERAPEUTIC DRUG MONITORING OF INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE

Sai Chuah, Miles Parkes

TRANSCRIPTOMIC PROFILES FOR HUMAN INTESTINAL T CELLS REVEAL NOVEL PATHWAYS OF REGULATION AND INTERACTIONS WITH GENETIC RISK FOR BOTH GASTROINTESTINAL AND EXTRAINTESTINAL INFLAMMATORY DISEASE.

Tim Raine, Jimmy Liu, Carl Anderson, Miles Parkes, Arthur Kaser

VEDOLIZUMAB SHOWS BETTER TREATMENT OUTCOMES THAN INFLIXIMAB FOR PATIENTS WITH ULCERATIVE COLITIS REFRACTORY TO TREATMENT WITH ADALIMUMAB: A PROPENSITY SCORE ANALYSIS OF UK IBD BIORESOURCE OUTCOMES

Christina Kapizioni, Miles Parkes, Tim Raine, Rofaida Desoki

Item 1 - 9 / 13
1
2